HomeCompareCRTX vs NOBL

CRTX vs NOBL: Dividend Comparison 2026

CRTX yields 102.56% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRTX wins by $4.30M in total portfolio value
10 years
CRTX
CRTX
● Live price
102.56%
Share price
$1.95
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.32M
Annual income
$1,481,817.76
Full CRTX calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — CRTX vs NOBL

📍 CRTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRTXNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRTX + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRTX pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRTX
Annual income on $10K today (after 15% tax)
$8,717.95/yr
After 10yr DRIP, annual income (after tax)
$1,259,545.10/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, CRTX beats the other by $1,259,332.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRTX + NOBL for your $10,000?

CRTX: 50%NOBL: 50%
100% NOBL50/50100% CRTX
Portfolio after 10yr
$2.17M
Annual income
$741,033.77/yr
Blended yield
34.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NOBL right now

CRTX
Analyst Ratings
1
Buy
4
Hold
3
Sell
Consensus: Hold
Altman Z
-4.0
Piotroski
2/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRTX buys
0
NOBL buys
0
No recent congressional trades found for CRTX or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRTXNOBL
Forward yield102.56%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.32M$22.9K
Annual income after 10y$1,481,817.76$249.78
Total dividends collected$3.87M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CRTX vs NOBL ($10,000, DRIP)

YearCRTX PortfolioCRTX Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$20,956$10,256.41$10,917$217.08+$10.0KCRTX
2$42,511$20,087.62$11,903$221.48+$30.6KCRTX
3$83,570$38,082.81$12,962$225.68+$70.6KCRTX
4$159,386$69,966.82$14,099$229.68+$145.3KCRTX
5$295,256$124,712.82$15,319$233.49+$279.9KCRTX
6$531,835$215,911.30$16,628$237.10+$515.2KCRTX
7$932,535$363,471.12$18,033$240.53+$914.5KCRTX
8$1,593,439$595,626.55$19,539$243.78+$1.57MCRTX
9$2,656,155$951,175.34$21,154$246.86+$2.64MCRTX
10$4,323,904$1,481,817.76$22,884$249.78+$4.30MCRTX

CRTX vs NOBL: Complete Analysis 2026

CRTXStock

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Full CRTX Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this CRTX vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRTX vs SCHDCRTX vs JEPICRTX vs OCRTX vs KOCRTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.